Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Oregon for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Oregon only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Oregon (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Dominik Sokalski (NPI 1104016278)

Field	Value
Entity Type	Individual
Organization	Dominik Sokalski
Address	1365 Poplar Dr
City	Medford
State	OR
ZIP	97504
Taxonomy	Rheumatology Physician
NPI Enumerated	July 25, 2007

Payer Source	Total Paid
Medicare	$2.3M
Medicaid	$0

Key Findings

Provider business model appears infusion‑focused with a rheumatology specialty emphasis: the top revenue codes are predominantly J‑codes for infused biologic agents (J0129, J1602, J9312) and infusion administration/chemotherapy-related codes (96413, 96415, 96365), indicating the practice delivers and bills for parenteral biologic therapies and infusion services rather than primarily office‑visit driven care. This mix suggests the practice operates an on‑site infusion service or infuses high‑cost biologics under physician supervision as a core service line.

Medicare revenue concentration is high and concentrated in a few biologics: Total Medicare revenue is $2.3M and the precomputed top 3 Medicare codes by revenue account for 64.8% of that total, signaling heavy dependence on abatacept (J0129), golimumab (J1602), and rituximab (J9312) as the primary revenue drivers. Reliance on a small set of high‑cost injectable therapies creates sensitivity of revenue to utilization and reimbursement changes for those agents.

This provider is effectively single‑payer with respect to public programs: Medicare revenue is $2.3M while there is no Medicaid billing on file, indicating no recorded Medicaid payer mix and making the provider operationally and financially dominated by Medicare market participation. Absence of Medicaid billing reduces exposure to that payer population and may reflect patient panel composition or contracting pattern in the region.

Competitive standing by code is mixed but shows national strength for several infusion products: the provider ranks at the 95th percentile nationally on J1602 (golimumab) and at the 90th percentile on J9312 (rituximab), indicating notably above‑typical to strong national volumes for those infused biologics. In contrast, J0129 (abatacept) is at the 86th percentile (typical, unremarkable volume) and several other biologic codes fall into mid‑to‑low percentile bands, so the practice is a major national contributor for selective drugs rather than uniformly dominant across all biologics.

Office evaluation & management volume is unusually concentrated per‑visit: 99214 generates $96.5K (4.3% of Medicare revenue) with a national rank placing the provider in the 98th percentile and labeled an extreme outlier, suggesting the practice records very high volume of moderate complexity established‑patient visits relative to peers. This combination of high established visit volume together with infusion services implies integrated clinic flows where many follow‑up encounters accompany ongoing biologic therapy.

Operational throughput for infusion support procedures is elevated: add‑on infusion time (96415) and initial infusion codes (96365) rank in high percentiles (96415 at the 96th percentile; 96365 at the 81st percentile) and together with chemotherapy/infusion administration code 96413 (95th percentile) this indicates above‑typical infusion throughput and experience administering multi‑hour or repeat infusions. These operational patterns support a business model with staffed infusion capacity and recurring patient infusions.

Lab and point‑of‑care testing are routine components of care: codes for metabolic panels (80053), CBC (85025), CRP (86140), and ESR (85651) are present among top codes and many sit at high national percentiles (80053 at 94th, 86140 at 94th, 85651 at 96th), reflecting consistent use of monitoring labs integral to rheumatology management of biologic therapy and disease activity monitoring. This indicates bundled clinical management accompanying infusion services rather than standalone drug‑only billing.

Provider tenure is long and establishes continuity: NPI was enumerated approximately 19 years ago (2007‑07‑25), indicating long‑standing Medicare participation and likely established referral relationships and operational stability in the local market. Longevity combined with concentrated biologic and infusion volumes suggests a mature practice with an established infusion program.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

47 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	17,580	$30	$580K
J1602	Injection, golimumab, 1 mg, for intravenous use	47,800	$10	$478K
J9312	Injection, rituximab, 10 mg	6,790	$60	$393.7K
J3262	Injection, tocilizumab, 1 mg	32,880	$10	$164.4K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	5,230	$30	$136K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	30,800	$1	$123.2K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,140	$90	$96.5K
Q5104	Injection, infliximab-abda, biosimilar, (renflexis), 10 mg	2,490	$30	$77.2K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	630	$100	$63.4K
J0897	Injection, denosumab, 1 mg	2,280	$20	$41K

Showing 1–10 of 47

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 47 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Oregon Distribution

Dominik Sokalski — 10 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Oregon

Full comparison — all codes billed, vs. state median

47 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	2	20	6,300	$30	$260.7K
J9312	1	10	3,750	$60	$220K
J3262	6	10	31,180	$1	$176.4K
J1602	1	20	13,600	$10	$156.4K
Q5104	3	10	3,850	$30	$129.7K
J0717	3	10	30,800	$1	$117.6K
J1745	7	20	3,750	$30	$115.2K
J0897	35	70	2,400	$20	$78.3K
96413	3	90	150	$100	$18.2K
86235	8	10	390	$20	$12.6K

Showing 1–10 of 47

Related Providers

Other providers that share a Tax Identification Number (TIN) with Dominik Sokalski, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Rheumatology Clinic LLC	OR	Rheumatology Physician	$0	$3.9M
David Chamberland	OR	Rheumatology Physician	$2.8M	$0
Giorgos Loizidis	PA	Rheumatology Physician	$31.8K	$0

Nearby Providers

Other providers in the same ZIP code as Dominik Sokalski, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Asante	OR	General Acute Care Hospital	$0	$29.7M
Addictions Recovery Center, Inc.	OR	Substance Abuse Rehabilitation Facility	$0	$29.2M
Asante Physician Partners	OR	Family Medicine Physician	$0	$27.2M
Mercy Flights Incorporated	OR	Ambulance	$3.6M	$19.4M
Providence Health & Services - Oregon	OR	General Acute Care Hospital	$0	$20.9M
Crc Health Oregon, LLC	OR	Methadone Clinic	$193K	$13M
James Kolby Robinson, Dmd	OR	Pediatric Dentistry	$0	$11.6M
Valley Immediate Care, LLC	OR	Urgent Care Clinic/Center	$0	$9.4M
Lincare Inc	OR	Durable Medical Equipment & Medical Supplies	$0	$7.1M
Southern Oregon Pediatrics, LLP	OR	Pediatric Hospice and Palliative Medicine Physician	$0	$6.5M

Dominik Sokalski — Billing Profile & Reimbursement Data

Sign up for Dominik Sokalski — Billing Profile & Reimbursement Data policy alerts

Dominik Sokalski — Billing Profile & Reimbursement Data

Sign up for Dominik Sokalski — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References